
Omnicell (OMCL) Stock Forecast & Price Target
Omnicell (OMCL) Analyst Ratings
Bulls say
Omnicell is well-positioned for growth in the healthcare automation sector, with a strong focus on providing cost-effective medication management solutions. The company has a track record of generating strong revenue through traditional market share gains, but recent conversations with non-OMCL customers and a significant increase in demo equipment requests suggest that competitive conversions will also be a major driver of future growth. With the recent launch of Titan XT and the Omnisphere platform, Omnicell is in a strong position to drive enterprise-wide standardization and long-term growth. Additionally, the company's positive customer feedback and continued investments in technology and software further solidify its position as a leading provider in the industry.
Bears say
Omnicell is well-positioned in the healthcare automation market with its software and services targeting cost-effective medication management for pharmacists and nurses. The company's recent guidance raise and strong margins indicate positive momentum, but the discount in valuation to its historical multiples suggests skepticism in the long-term growth potential amidst potential competition. Nonetheless, the launch of the Titan XT series cabinets and potential conversions during the replacement cycle could lead to healthy incremental revenues, and the 5-year average multiple of ~20x may eventually be warranted.
This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.
Omnicell (OMCL) Analyst Forecast & Price Prediction
Start investing in Omnicell (OMCL)
Order type
Buy in
Order amount
Est. shares
0 shares